Navigation Links
VaxGen Files First Quarter 2007 Financials
Date:9/21/2007

SOUTH SAN FRANCISCO, Calif., Sept. 21 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that it has filed with the Securities and Exchange Commission (SEC) its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. The report can be found at the link titled "SEC Filings" in the Investor Relations section of VaxGen's web site at http://www.vaxgen.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

The only financial statements the company has outstanding before it regains compliance with its SEC financial reporting obligations are the Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, which is currently under review by VaxGen and its independent auditors. Once VaxGen is current with its financial statements, the company intends to apply for listing on a national stock exchange.

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the anticipated filing of the company's outstanding quarterly reports and its application for listing of its common stock. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. PCR Polymerases Application Profiles
2. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Successful stabilization of gene expression profiles
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Third Wave files countersuit vs. Digene in patent case
7. TomoTherapy files registration statement for IPO
8. Merge files financial reports by market opening
9. The Why Files celebrates decade of science exploration
10. Third Wave files patent suits against Digene, Chiron and Bayer
11. New Web virus could lead to lost files, extortion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for ... Breast Cancer Symposium. Using molecular test results from tumors with previously documented ...
(Date:12/2/2016)... ... , ... DrugDev believes the only way to achieve real change ... three tenets were on display at the 2nd Annual DrugDev User Summit (hosted by ... and site organizations to discuss innovation and the future of clinical research. , ...
(Date:12/2/2016)... YORK , Dec. 1, 2016   SurePure, ... photopurification, announced today that the Company has concluded an ... the right for a 90-day period to acquire units ... value of approximately USD 3.7 million.  ... agreement with Tamarack under which Tamarack will seek regulatory ...
(Date:11/30/2016)... 2016  GenomOncology today announced the appointment of Joshua ... Dr. Coleman will oversee clinical content development ... platform. The GenomOncology software suite empowers molecular pathologists with a ... clinical decision support, from quality control through reporting. ... , , ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):